Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, June 21, 2023.
The partnership between Nuwellis and DaVita to launch an ultrafiltration therapy pilot program is an exciting development in the field of renal care. The agreement enables Nuwellis — formerly CHF Solutions — to pilot its Aquadex ultrafiltration therapy within selected U.S. markets. Fast Five hosts Sean Whooley and Danielle Kirsh discuss the partnership in detail and what executives say about it.
CorWave’s successful fundraising of $64 million is a significant milestone for the company as it prepares to manufacture its left ventricular assist device (LVAD). LVADs play a critical role in supporting patients with advanced heart failure, and CorWave’s technology has the potential to improve patient outcomes and enhance their quality of life. Learn more about the company’s technology and other developments in today’s episode.
Avanos Medical’s decision to acquire Diros Technology is a strategic move demonstrating the company’s commitment to expanding its portfolio and addressing unmet needs in the medical device market. Diros Technology makes radiofrequency products that are used to treat chronic pain conditions. Whooley explains how the acquisition will support Avanos’ offerings and when the transaction will be completed.
The FDA approval of Surmodics’ SurVeil drug-coated balloon highlights the continued advancements in interventional cardiology and the increasing availability of innovative treatment options for patients with peripheral arterial disease (PAD). Hear how the technology stacks up against other devices in the market and how the company overcame being “unapprovable” earlier this year.
BD’s decision to sell its surgical instrumentation assets to Steris for $540 million marks a strategic move to streamline its portfolio and focus on core areas of expertise. This transaction enables BD to allocate resources more effectively and invest in research and development efforts that align with its long-term growth strategy. Whooley and Kirsh explain how BD will expand and how the acquisition will affect Steris’ bottom line.
Subscribe to the Fast Five daily news podcast on your preferred listening platform. If you’re on a desktop computer, scan the QR code below with your smartphone to easily access the podcast on your mobile device.
Listen to previous episodes here.